Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: Risk assessment of acylglucuronides using human hepatocytes

Xenobiotica

Volumn 44, Issue 8, 2014, Pages 677-686

  Jinno, Norimasa ^a,b   Tagashira, Mizuka ^a   Tsurui, Kazuyuki ^a   Yamada, Shizuo ^b  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

( ) borneol; 1 aminobenzotriazole; Acylglucuronide; Cytochrome P450; Human hepatocyte; UDP glucuronosyltransferase

Indexed keywords

BUFURALOL; CARBOXYLIC ACID; CYTOCHROME P450; DICLOFENAC; FLUFENAMIC ACID; FUROSEMIDE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE; IBUFENAC; IBUPROFEN; IMIPRAMINE; INDOMETACIN; KETOPROFEN; LEVOFLOXACIN; LIDOCAINE; MEFENAMIC ACID; METOPROLOL; MIDAZOLAM; MONTELUKAST; NALOXONE; NAPROXEN; NIFEDIPINE; PROBENECID; REPAGLINIDE; TELMISARTAN; TIENILIC ACID; TOLMETIN; UNINDEXED DRUG; VALSARTAN; ZOMEPIRAC; 1-AMINOBENZOTRIAZOLE; BORNANE DERIVATIVE; GLUCURONIDE; ISOBORNEOL; TRIAZOLE DERIVATIVE;

ARTICLE; DRUG METABOLISM; DRUG STABILITY; HUMAN; LIVER CELL; METABOLIC ACTIVATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INACTIVATION; ENZYME SPECIFICITY; ENZYMOLOGY; HALF LIFE TIME; LIVER; METABOLISM; RISK ASSESSMENT; STANDARD;

BORNANES; CARBOXYLIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HEPATOCYTES; HUMANS; INACTIVATION, METABOLIC; LIVER; REFERENCE STANDARDS; RISK ASSESSMENT; SUBSTRATE SPECIFICITY; TRIAZOLES;

EID: 84903941717     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.894219     Document Type: Article

References (42)

1. Baillie TA. (2006). Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19: 889-93. (Pubitemid 44092354)
2. Bauman JN, Kelly JM, Tripathy S, et al. (2009). Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22: 332-40.
3. Benet LZ, Spahn-Langguth H, Iwakawa S, et al. (1993). Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141-6.
4. Bolze S, Lacombe O, Durand G, et al. (2002). Standardization of a LC/ MS/MS method for the determination of acyl glucuronides and their isomers. Curr Sep 20: 55-9.
5. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10: 1093-5. (Pubitemid 23211439)
6. Di L, Umland JP, Chang G, et al. (2011). Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39: 1270-7.
7. Di L, Keefer C, Scott DO, et al. (2012). Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57: 441-8.
8. Ebner T, Heinzel G, Prox A, et al. (1999). Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27: 1143-9. (Pubitemid 29463600)
9. Emoto C, Murase S, Sawada Y, et al. (2003). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18: 287-95.
10. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. (2004). Drugprotein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17: 3-16. (Pubitemid 38134055)
11. Ishii Y, Iida N, Miyauchi Y, et al. (2012). Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols. Biol Pharm Bull 35: 1811-17.
12. Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73: 147-71. (Pubitemid 27191615)
13. Jean P, Lopez-Garcia P, Dansette P, et al. (1996). Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur J Biochem 241: 797-804. (Pubitemid 26379382)
14. Jinno N, Ohashi S, Tagashira M, et al. (2013). A simple method to evaluate reactivity of acylglucuronides optimized for early stage drug discovery. Biol Pharm Bull 36: 1509-13.
15. Jones RD, Jones HM, Rowland M, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 100: 4074-89.
16. Kaplowitz N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4: 489-99. (Pubitemid 40861991)
17. Kimoto E, Walsky R, Zhang H, et al. (2012). Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes. Drug Metab Dispos 40: 407-11.
18. Koga T, Fujiwara R, Nakajima M, Yokoi T. (2011). Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. Drug Metab Dispos 39: 54-60.
19. Li AP. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the ''multiple determinant hypothesis'' for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142: 7-23. (Pubitemid 35232550)
20. Lombardo F, Waters NJ, Argikar UA, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53: 167-77.
21. Lombardo F, Waters NJ, Argikar UA, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53: 178-91.
22. Mano Y, Usui T, Kamimura H. (2007). The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35: 2040-4. (Pubitemid 350005193)
23. Masubuchi N, Makino C, Murayama N. (2007). Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol 20: 455-64. (Pubitemid 46548692)
24. Naisbitt DJ, Sanderson LS, Meng X, et al. (2007). Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 168: 45-50. (Pubitemid 44909720)
25. Nakayama S, Atsumi R, Takakusa H, et al. (2009). A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37: 1970-7.
26. Nakayama S, Takakusa H, Watanabe A, et al. (2011). Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab Dispos 39: 1247-54.
27. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. (2008). Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21: 1814-22.
28. Reese M, Sakatis M, Ambroso J, et al. (2010). An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem Biol Interact 192: 60-4.
29. Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100: 4090-110.
30. Roberts MS, Rowland M. (1986). Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38: 177-81. (Pubitemid 16162503)
31. Sakaguchi K, Green M, Stock N, et al. (2004). Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 424: 219-25. (Pubitemid 38401955)
32. Sawamura R, Okudaira N, Watanabe K, et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38: 1857-64.
33. Shibata Y, Takahashi H, Chiba M, Ishii Y. (2002). Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30: 892-6. (Pubitemid 34815418)
34. Spahn-Langguth H, Benet LZ. (1992). Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24: 5-47.
35. Sohlenius-Sternbeck AK, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40: 637-49.
36. Sohlenius-Sternbeck AK, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42: 841-53.
37. Thompson RA, Isin EM, Li Y, et al. (2010). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192: 65-71.
38. Thompson RA, Isin EM, Li Y et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25:161632.
39. Uetrecht J. (2001). Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Dev 4: 55-9. (Pubitemid 32118459)
40. Uetrecht J. (2007). Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47: 513-39.
41. Usui T, Mise M, Hashizume T, et al. (2009). Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37: 2383-92.
42. Vuppugalla R, Marathe P, He H, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100: 4111-26.